Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $19.7 million.

  • Corcept Therapeutics' Profit After Tax fell 5834.2% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.1 million, marking a year-over-year decrease of 2517.88%. This contributed to the annual value of $141.2 million for FY2024, which is 3304.03% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Profit After Tax of $19.7 million as of Q3 2025, which was down 5834.2% from $35.1 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Profit After Tax ranged from a high of $47.2 million in Q3 2024 and a low of $15.9 million during Q1 2023
  • Its 5-year average for Profit After Tax is $28.2 million, with a median of $27.8 million in 2024.
  • In the last 5 years, Corcept Therapeutics' Profit After Tax surged by 8887.42% in 2023 and then plummeted by 5834.2% in 2025.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Profit After Tax stood at $32.1 million in 2021, then crashed by 48.21% to $16.6 million in 2022, then soared by 88.87% to $31.4 million in 2023, then dropped by 1.94% to $30.7 million in 2024, then crashed by 36.03% to $19.7 million in 2025.
  • Its Profit After Tax stands at $19.7 million for Q3 2025, versus $35.1 million for Q2 2025 and $20.5 million for Q1 2025.